CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro

The goal of targeted immunotherapy in cancer is to damage both malignant and tumor-supporting cells of the microenvironment but spare unaffected tissue. The malignant cells in classical Hodgkin lymphoma (cHL) selectively express CD30. They release this receptor on extracellular vesicles (EVs) for th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hansen, Hinrich P., Trad, Ahmad, Dams, Maria, Zigrino, Paola, Moss, Marcia, Tator, Maximilian, Schön, Gisela, Grenzi, Patricia C, Bachurski, Daniel, Aquino, Bruno, Dürkop, Horst, Reiners, Katrin S, von Bergwelt-Baildon, Michael, Hallek, Michael, Grötzinger, Joachim, Engert, Andreas, Leme, Adriana F Paes, von Strandmann, Elke Pogge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058698/
https://www.ncbi.nlm.nih.gov/pubmed/27105521
http://dx.doi.org/10.18632/oncotarget.8864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058698/
https://www.ncbi.nlm.nih.gov/pubmed/27105521
http://dx.doi.org/10.18632/oncotarget.8864

Ejemplares similares